Drug General Information (ID: DDIKIXEJNA)
Drug Name			Aldesleukin		Drug Info		Iohexol		Drug Info
Drug Type		Interferons				Small molecule
Therapeutic Class		Antineoplastics				Non-Ionic Iodinated Contrast Media

Mechanism of Aldesleukin-Iohexol Interaction (Severity Level: Major)
Increased risk of lowers seizure threshold Click to Show/Hide Mechanism Graph
Drug Name		Aldesleukin				Iohexol
Mechanism		Lower seizure threshold				Lower seizure threshold
Key Mechanism Factor 1
		Factor Name		Lowers seizure threshold
		Factor Description		The combination of medications that lower the seizure threshold is a factor that makes people with epilepsy more likely to have seizures. A seizure is a sudden, uncontrolled electrical disturbance in the brain that can cause changes in your behavior, movements or sensations, and level of consciousness.
Mechanism Description		Increased risk of lowers seizure threshold by the combination of Aldesleukin and Iohexol

Recommended Action
Management		Aldesleukin should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media. Patients should be monitored for adverse reactions during and after the myelography, and symptomatic treatment initiated as clinically appropriate.

References
1	Product Information. Osmovist 240 (iotrolan). Berlex Canada Inc, Lachine, QC.
2	Product Information. Proleukin (aldesleukin). Chiron Therapeutics, Emeryville, CA.